

Iceland 
Liechtenstein
Norway grants

“Working together for
a green, competitive and inclusive Europe”

“HE-RO-IS strategic cooperation in hematology”

F SEE 2014-2021 No. 19-COP-0031

Student Mobility STMS C1

The 6th - 11th of May 2021

Disclaimer: This STMS event was realised with the EEA Financial Mechanism 2014-2021 financial support. Its content (text, photos, videos) does not reflect the official opinion of the Programme Operator, the National Contact Point and the Financial Mechanism Office. Responsibility for the information and views expressed therein lies entirely with the author(s).

HEMOPHILIA

A microscopic image of a virus particle, likely HIV, with the word "HEMOPHILIA" overlaid in large, pink, 3D-style letters. The background is a dark red color with various cellular structures and other virus particles visible.

DAY 1. Introduction

What is hemophilia?

Pathophysiology of hemophilia

DAY 2. Diagnosis

Clinical diagnosis:


particularities in childhood,
adolescence, adulthood

Laboratory diagnosis: common
coagulation assays, one-step,
two step coagulometric factor
determination assays,
colorimetric assays

Genetic testing: confirmation
and prenatal screening
Particularities of different age
groups

Ciprian Tomuleasa, M.D., PhD





DAY 3. Management of the hemophilic patient
General management of hemophilia
Prophylactic treatment in children and adults

Reykjavik University, Iceland, May 2021, Student Mobility to Reykjavik





Student working in the hematology laboratory

Replacement therapy in hemophilia

New molecules and how to use them

Complementary management of the hemophilic patient

